PREVIOUS
✖
2DG adjunct therapy in Covid treatment
June 4 , 2021
1328 days
817
0
- The Defence Research and Development Organisation (DRDO) announced that the anti-COVID drug 2DG has been approved for emergency use as an adjunct therapy in the treatment of COVID-19 patients.
- DCGI approved the emergency use authorization of 2-deoxy-D-glucose (2-DG).
- It was approved as an adjunct therapy for moderate to severe COVID-19 patients.
Leave a Reply
Your Comment is awaiting moderation.